Zymeworks Inc. officer Paul Andrew Moore filed a Form 144 notice of proposed sale on November 13, 2026, covering 39,741 shares of Zymeworks common stock with an aggregate market value of $1,051,944.27.

Key Highlights

  • Proposed seller: Paul Andrew Moore, identified as an officer of Zymeworks Inc.
  • Shares proposed for sale: 39,741 shares of common stock, with an aggregate market value of $1,051,944.27.
  • Shares outstanding: 69,030,691 shares of common stock outstanding, according to the filing.
  • Approximate sale date: November 13, 2026, through broker Morgan Stanley Wealth Management Canada.
  • Sources of shares: 7,367 shares from restricted stock unit vesting on January 5, 2024; 7,374 shares from RSU vesting on January 6, 2025; and 25,000 shares from option exercise on November 13, 2026.
  • No sales in prior three months: The filing reports nothing to report for securities sold during the past three months.

Zymeworks Officer Moore Proposes Sale of Common Stock Acquired via RSUs and Option Exercise

According to the Form 144 filed with the U.S. Securities and Exchange Commission, Paul Andrew Moore, an officer of Zymeworks Inc. (NASDAQ:ZYME), proposed to sell 39,741 shares of Zymeworks common stock on or around November 13, 2026. The filing lists Morgan Stanley Wealth Management Canada, located at 140 4th Ave. SW, Suite 2740, Calgary, as the named broker for the transaction.

The filing details three separate acquisition events underlying the shares proposed for sale. A total of 7,367 shares were acquired through the vesting of restricted stock units from the issuer on January 5, 2024, with payment described as vesting of award on that same date. An additional 7,374 shares were acquired through RSU vesting from the issuer on January 6, 2025, again with payment described as vesting of award. The remaining 25,000 shares were acquired through the exercise of options from the issuer on November 13, 2026, with the nature of payment described as "Exercise and sell to cover."

The filing states that the aggregate market value of the 39,741 shares proposed for sale is $1,051,944.27, against a total of 69,030,691 shares of Zymeworks common stock outstanding. The filing reports no sales of Zymeworks securities by Moore during the three months preceding the notice date. Zymeworks Inc. is listed on Nasdaq and is located at 108 Patriot Drive, Suite A, Middletown, Delaware 19709.

What Was Disclosed

Zymeworks officer Paul Andrew Moore filed a Form 144 on November 13, 2026, disclosing a proposed sale of 39,741 shares of common stock valued at $1,051,944.27, sourced from two RSU vestings and one option exercise, with no prior-quarter sales reported.